Cerus (CERS) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1 year price targets for Cerus' shares. Their CERS share price forecasts range from $3.75 to $6.00. On average, they anticipate the company's share price to reach $4.88 in the next twelve months. This suggests a possible upside of 200.9% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.

Cerus' stock was trading at $3.65 at the beginning of the year. Since then, CERS shares have decreased by 55.6% and is now trading at $1.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CERS earnings forecast.

Cerus Co. (NASDAQ:CERS) announced its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The biotechnology company had revenue of $38.85 million for the quarter, compared to the consensus estimate of $40.80 million. Cerus had a negative net margin of 33.24% and a negative trailing twelve-month return on equity of 80.35%.

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK).

Cerus updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $172.56 million.

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CERS stock can currently be purchased for approximately $1.62.

Cerus (NASDAQ:CERS) has a market capitalization of $292.90 million and generates $162.05 million in revenue each year. The biotechnology company earns $-42,780,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

The company employs 665 workers across the globe.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.